Antibiotic Mechanisms and Resistance - Ninth Grade Science
The discovery and development of antimicrobial drugs during the twentieth century transformed clinical medicine, turning once-fatal bacterial infections into manageable, curable conditions. However, the therapeutic power of antibiotics is governed by strict biochemical rules of selective toxicity, and their widespread misuse has catalyzed the emergence of antibiotic-resistant bacterial strains, creating one of modern medicine's greatest challenges.
The Principle of Selective Toxicity
The foundational pharmacological principle governing all antimicrobial chemotherapy is selective toxicity. Formulated by the German medical researcher Paul Ehrlich, selective toxicity dictates that an effective antimicrobial drug must inhibit or destroy a pathogenic microorganism without exerting unacceptable toxic damage to the cells and tissues of the human host.
THE TARGET DYNAMICS OF SELECTIVE TOXICITY
=========================================
ANIMAL (HUMAN) CELL BACTERIAL PATHOGEN CELL
------------------- -----------------------
- No cell wall - Rigid PEPTIDOGLYCAN cell wall
- 80S Ribosomes (40S + 60S) - 70S Ribosomes (30S + 50S)
- Cholesterol in membrane - Ergosterol / Unique hopanoids
- Linear DNA with histones - Circular DNA with DNA GYRASE
- Diet-derived Folic Acid - Synthesizes FOLIC ACID de novo
| |
v v
[ DRUG HAS NO EFFECT ] [ ANTIBIOTIC INHIBITS TARGET ]
Human cells survive undamaged Bacterial cell dies or halts growth
Selective toxicity is achieved by designing chemical agents that target biochemical structures, metabolic pathways, or enzymes unique to the pathogen that are completely absent or structurally distinct in human host cells.
Major Cellular Targets of Antibiotics
Medical science groups antibacterial antibiotics into five primary biochemical mechanisms based on the bacterial structures they disrupt:
THE FIVE PRIMARY MECHANISMS OF ANTIBIOTIC ACTION
================================================
1. Cell Wall Synthesis Inhibition
(Penicillins, Cephalosporins, Vancomycin)
|
v
2. Protein Synthesis +---------------+ 3. Nucleic Acid Synthesis
Inhibition | BACTERIAL | Inhibition
- 50S: Macrolides, | CELL | - DNA Gyrase: Fluoroquinolones
Chloramphenicol +---------------+ - RNA Polymerase: Rifampin
- 30S: Tetracyclines, |
Aminoglycosides v
4. Cell Membrane Disruption
(Polymyxins, Daptomycin)
|
v
5. Antimetabolite Pathway Blockade
(Sulfonamides, Trimethoprim -> Folic Acid)
1. Inhibition of Bacterial Cell Wall Synthesis
Bacterial cells maintain high internal osmotic pressure (up to 20 atmospheres in Gram-positive bacteria). To prevent osmotic lysis, bacteria encase their plasma membranes in a rigid cell wall composed of cross-linked peptidoglycan.
Beta-lactam antibiotics, which include penicillins (e.g., penicillin G, amoxicillin) and cephalosporins, possess a four-membered beta-lactam ring that acts as a structural analog to the terminal D-alanyl-D-alanine dipeptide of peptidoglycan chains. Beta-lactams bind to and permanently inhibit bacterial transpeptidase enzymes (also known as penicillin-binding proteins), which catalyze the cross-linking of adjacent peptidoglycan polymer strands.
As the growing bacterium attempts to expand, it synthesizes un-crosslinked, structurally weakened cell wall segments. Unable to withstand its internal turgor pressure, water rushes into the hypertonic cytoplasm, causing the bacterial cell to rupture and lyse (bactericidal action). Because human animal cells possess no peptidoglycan cell walls, beta-lactam antibiotics exhibit exceptional selective toxicity, causing minimal side effects in human cells unless the patient has an allergic drug hypersensitivity.
PEPTIDOGLYCAN TRANSPEPTIDATION BLOCKADE
=======================================
Normal Wall Synthesis:
Peptidoglycan Strand ==== Transpeptidase Cross-Link ====> Strong Rigid Wall
In the Presence of Penicillin:
Penicillin binds Transpeptidase ----X (Blockade) ----> Uncrosslinked Weak Wall
|
v
Osmotic Cell Lysis!
2. Inhibition of Bacterial Protein Synthesis
Protein synthesis is essential for cellular survival, growth, and replication. Bacteria translate messenger RNA into proteins using 70S ribosomes (composed of a 50S and a 30S subunit), whereas eukaryotic human cells possess 80S cytoplasmic ribosomes (composed of a 60S and a 40S subunit). This structural difference permits antibiotics to selectively bind to bacterial ribosomal subunits, shutting down protein synthesis without arresting human cytoplasmic ribosomes.
Inhibitors of the 30S Subunit: Aminoglycosides (e.g., streptomycin, gentamicin) bind irreversibly to the 30S subunit, distorting its proofreading conformation and causing premature termination or misreading of genetic codons. Tetracyclines (e.g., doxycycline) bind reversibly to the 30S subunit, physically blocking incoming aminoacyl-tRNA molecules from docking at the ribosomal A-site, arresting peptide elongation.
Inhibitors of the 50S Subunit: Macrolides (e.g., erythromycin, azithromycin) bind to the 50S subunit and inhibit the translocation step, preventing the ribosome from advancing along the mRNA strand. Chloramphenicol binds to the 50S subunit and blocks peptidyl transferase, preventing peptide bond formation between adjacent amino acids.
3. Inhibition of Nucleic Acid Synthesis
Bacterial replication and gene transcription require specialized enzymes to manage nucleic acids:
Fluoroquinolones (e.g., ciprofloxacin, levofloxacin) inhibit bacterial DNA gyrase (topoisomerase II) and topoisomerase IV. DNA gyrase introduces negative supercoils into bacterial circular DNA to relieve torsional strain during replication fork advancement. Inhibiting DNA gyrase leads to double-stranded DNA breaks and arrests bacterial chromosomal replication.
Rifamycins (e.g., rifampin) bind specifically to bacterial DNA-dependent RNA polymerase, blocking the initiation of messenger RNA synthesis without inhibiting eukaryotic RNA polymerases, making it an essential drug for treating Mycobacterium tuberculosis.
4. Disruption of Cell Membrane Architecture
Certain antibiotics alter the physical integrity of bacterial plasma membranes. Polymyxins (e.g., polymyxin B, colistin) act like cationic detergents: their positively charged peptide rings bind to the negatively charged lipopolysaccharides of Gram-negative outer membranes, while their hydrophobic fatty acid tails insert into the lipid bilayer. This disrupts membrane integrity, causing leakage of intracellular purines, pyrimidines, and potassium ions, leading to rapid cell death.
5. Antimetabolite Competitive Inhibition
Bacteria must synthesize folic acid (vitamin $B_9$) *de novo* from para-aminobenzoic acid (PABA) to manufacture thymidine, purines, and amino acids. Humans cannot synthesize folic acid and must absorb it pre-formed from dietary foods.
Sulfonamides (sulfa drugs) are close structural analogs of PABA. They act as competitive inhibitors for the active site of the bacterial enzyme dihydropteroate synthase, shutting down folic acid synthesis. When paired with trimethoprim (which inhibits the subsequent enzyme dihydrofolate reductase), the combination shuts down bacterial nucleotide synthesis.
SULFONAMIDE COMPETITIVE INHIBITION OF FOLIC ACID
================================================
Normal Pathway:
PABA + Pteridine ===== Dihydropteroate Synthase =====> Folic Acid
Sulfonamide Action:
Sulfonamide (PABA Mimic) binds enzyme active site -----X (Competitive Block)
|
v
No Folic Acid Produced
(Bacterial Death)
Why Antibiotics Are Ineffective Against Viruses
A frequent medical misconception is the expectation that antibiotics can treat viral infections, such as the common cold, viral bronchitis, or influenza.
ANTIBIOTICS VERSUS VIRUSES: WHY DRUGS FAIL
==========================================
Antibiotic Drug Target Status in Viral Structure
------------------------------------------------------------------------
Peptidoglycan Cell Wall Viruses completely lack cell walls;
(Targeted by Penicillins) surrounded by protein capsid
70S Bacterial Ribosome Viruses have NO ribosomes; use human
(Targeted by Tetracyclines) host 80S ribosomes for translation
Bacterial DNA Gyrase Viruses lack DNA gyrase; utilize host
(Targeted by Ciprofloxacin) enzymes or distinct viral polymerases
Bacterial Metabolic Pathways Viruses possess NO autonomous metabolism,
(Targeted by Sulfa Drugs) no cytoplasm, and no energy pathways
Antibiotics function by disrupting bacterial biochemical structures and metabolic pathways. Viruses share none of these features: they lack peptidoglycan cell walls, possess no ribosomes, have no independent metabolic pathways, and replicate entirely by hijacking the biochemical machinery of living human host cells. Administering penicillin or azithromycin for a viral cold cannot harm the virus; instead, it unnecessarily exposes the patient's normal, beneficial bacterial microbiome to antibiotic selection pressure, fostering drug resistance.
Treating viral infections requires antiviral drugs (e.g., oseltamivir for influenza, acyclovir for herpesviruses, antiretrovirals for HIV), which inhibit specific viral enzymes, such as viral reverse transcriptase, viral protease, or viral neuraminidase.
Mechanisms of Bacterial Antibiotic Resistance
Bacteria evolve resistance to antimicrobial drugs through spontaneous genetic mutations or through horizontal gene transfer via plasmids (R-plasmids) acquired through conjugation, transformation, or transduction.
FOUR PRIMARY BIOCHEMICAL MECHANISMS OF DRUG RESISTANCE
======================================================
1. Enzymatic Inactivation of Drug:
Bacterial Beta-Lactamase enzyme hydrolyzes the beta-lactam ring of penicillin
2. Target Modification / Mutation:
Mutational alteration in 30S/50S ribosomal protein or DNA gyrase structure
prevents the drug from binding while preserving normal bacterial function
3. Efflux Pump Overexpression:
Membrane transport pumps actively export antibiotic molecules out of the
cytoplasm as fast as they enter, keeping intracellular drug levels low
4. Decreased Permeability / Porin Loss:
Gram-negative bacteria downregulate or alter outer membrane porin proteins,
blocking hydrophilic antibiotics from crossing into the periplasm
Enzymatic Inactivation: Bacteria produce enzymes that neutralize the drug. Beta-lactamase (penicillinase) enzymes hydrolyze the essential beta-lactam ring of penicillins, rendering them inactive.
Target Modification: Mutations change the structure of the antibiotic's target binding site without destroying its biological function. For example, methicillin-resistant Staphylococcus aureus (MRSA) acquired the mecA gene, which encodes an altered penicillin-binding protein (PBP2a) to which beta-lactam drugs cannot bind.
Efflux Pumps: Bacteria express membrane protein pumps that capture antibiotic molecules entering the cytoplasm and pump them back out into the external environment, keeping intracellular drug levels below lethal thresholds (a common mechanism against tetracyclines).
Decreased Permeability: Gram-negative bacteria downregulate outer membrane porin channels, preventing hydrophilic antibiotics (such as aminoglycosides and carbapenems) from entering the cell.
Stewardship and Preventing the Antimicrobial Resistance Crisis
The emergence of multidrug-resistant "superbugs" threatens to return modern clinical medicine to a pre-antibiotic era where routine infections and surgical procedures become life-threatening. Preventing this crisis requires strict antibiotic stewardship:
Prudent Prescribing: Healthcare practitioners must prescribe antibiotics only for confirmed bacterial infections, never for viral respiratory illnesses, and should use targeted narrow-spectrum antibiotics based on laboratory culture and sensitivity testing whenever possible.
Patient Adherence: Patients must complete their entire prescribed antibiotic course, even if symptoms improve early. Discontinuing therapy prematurely leaves behind partially resistant bacterial sub-populations, which can multiply and cause a recurrent, drug-resistant infection.
Agricultural Restrictions: Prohibiting the use of medically important antibiotics as sub-therapeutic growth promoters in livestock feed, a practice that historically accelerated environmental selection of resistant bacterial strains.
Chapter Exercises
Exercise 1: Define the concept of selective toxicity in pharmacology, explaining how it enables antibiotics to destroy bacteria without causing systemic toxicity to human host cells.
Exercise 2: Describe the biochemical mechanism of action of beta-lactam antibiotics, detailing how inhibiting peptidoglycan transpeptidation leads to bacterial cell lysis.
Exercise 3: Explain why antibiotics designed to treat bacterial infections are ineffective against viral diseases such as influenza and the common cold.
Exercise 4: Outline four distinct biochemical mechanisms through which bacteria develop resistance to antimicrobial medications.
Exercise 5: Explain why a patient prescribed a seven-day course of antibiotics must complete the entire regimen even if they feel fully recovered by day three.
Solutions and Explanations
Solution 1: Selective toxicity is the pharmacological principle whereby an antimicrobial agent selectively inhibits or kills a pathogenic microbe without causing significant adverse chemical damage to the human host. It relies on fundamental biochemical differences between prokaryotic pathogens and eukaryotic animal cells. Antibiotics are engineered to target cellular structures, metabolic pathways, or enzymes unique to bacteria—such as the peptidoglycan cell wall, the 70S bacterial ribosome, and the DNA gyrase enzyme—which are completely absent or structurally distinct in human cells, allowing the drug to destroy the bacterium while leaving human tissues unaffected.
Solution 2: Beta-lactam antibiotics (e.g., penicillin) contain a four-membered beta-lactam ring that mimics the terminal D-alanyl-D-alanine chemical structure of nascent peptidoglycan chains. During bacterial cell wall synthesis, the beta-lactam drug binds covalently to the active site of bacterial transpeptidase enzymes (penicillin-binding proteins), permanently blocking them from forming peptide cross-links between adjacent glycan chains. Consequently, the newly synthesized cell wall is weak and defective. Because bacteria maintain high internal osmotic pressure, water rushes into the hypertonic cell through osmosis, stretching the fragile membrane until it bursts, killing the bacterium through osmotic lysis.
Solution 3: Antibiotics are engineered exclusively to target bacterial structures, enzymes, and metabolic pathways, including peptidoglycan cell walls, 70S ribosomes, bacterial DNA gyrase, and autonomous folic acid synthesis. Viruses possess none of these features. A virus is an acellular package containing a DNA or RNA core enclosed in a protein capsid, completely lacking a cell wall, ribosomes, cytoplasm, and independent metabolic pathways. Because viruses replicate entirely by entering human host cells and utilizing human host 80S ribosomes and polymerases, antibiotics find no bacterial targets to bind and are incapable of disrupting viral replication.
Solution 4: Bacteria develop antibiotic resistance through four primary mechanisms. First, enzymatic inactivation: producing enzymes such as beta-lactamases that chemically hydrolyze and deactivate the antibiotic before it acts. Second, target site modification: mutational changes in the bacterial binding site (such as altering ribosomal RNA or producing mutant penicillin-binding proteins like PBP2a in MRSA) that prevent the antibiotic from binding while preserving cellular function. Third, active efflux pumping: expressing transport pumps in the cell membrane that capture antibiotic molecules and pump them out of the cell, preventing lethal intracellular drug buildup. Fourth, reduced membrane permeability: down-regulating outer membrane porin channels in Gram-negative bacteria, blocking the antibiotic from crossing the outer membrane.
Solution 5: When an antibiotic course begins, the drug rapidly eliminates the most vulnerable, drug-susceptible bacteria, relieving symptoms within two to three days. However, a sub-population of hardier, moderately resistant bacteria survives longer. If the patient stops taking the medication early, the concentration of the antibiotic in the bloodstream drops below therapeutic thresholds. The surviving, moderately resistant bacteria resume rapid multiplication, causing a relapse of the infection. More seriously, these surviving bacteria are now enriched for resistant traits and can acquire mutations granting full resistance, producing a recurrent infection that cannot be cured by that antibiotic and can spread to other individuals in the community.